RBM45 and Alzheimer disease: FTLD-TDP subjects exhibited significantly more RBM45 inclusions than non-neurologic disease controls, AD, or ALS subjects (Fig. 7e; p < 1 × 10− 6 for control and AD and p < 0.01 for ALS versus FTLD-TDP, respectively).